Findings

What do systematic reviews say?

116 questions · 120 findings · 11 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 48 · 40%GRADE not reported 1 · 0.8%Very low 26 · 21.7%Low 28 · 23.3%Moderate 16 · 13.3%High 1 · 0.8%

Oestrogen therapy alone vs surgery

Participant adherence to intervention · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs surgery

Minor adverse effects: vaginal events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs surgery

Major adverse events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs no treatment or placebo

Objective improvement or cure of POP symptoms · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs no treatment or placebo

Generic quality of life measures · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs no treatment or placebo

Participant adherence to intervention · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs no treatment or placebo

Minor adverse effects: vaginal events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs no treatment or placebo

Major adverse events · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs pelvic floor muscle training (PFMT)

Subjective improvement or cure of POP symptoms · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs pelvic floor muscle training (PFMT)

Improvement or cure of associated sexual symptoms · women with POP

The review found no eligible studies for this question.

1 finding from 1 review

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen

Symptoms score: Premenstrual Daily Questionnaire (PDQ) Scale from 0 to 30, with a higher score indicating a worse outcome over 8 months · women with PMS

1 finding from 1 review

Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 98 participants
Very low

Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen

Withdrawals due to adverse events · women with PMS

It is very uncertain whether dose comparison: oestrogen 100 µg patch changes adverse events ‐ withdrawal rates over 8 months' compared with 200 µg patch plus progestogen (very low certainty).

1 finding from 1 review

Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
RR 0.7 [0.34, 1.46]
1 study · 107 participants
Very low

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

Uterine volume (cm³) · girls with Turner syndrome who were treated with prepubertal growth hormone

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

Endometrial thickness (mm) · girls with Turner syndrome who were treated with prepubertal growth hormone

The review found no eligible studies for this question.

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

Endometrial histology · girls with Turner syndrome who were treated with prepubertal growth hormone

The review found no eligible studies for this question.

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

Uterine perfusion · girls with Turner syndrome who were treated with prepubertal growth hormone

The review found no eligible studies for this question.

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

Reproductive outcomes · girls with Turner syndrome who were treated with prepubertal growth hormone

The review found no eligible studies for this question.

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

Adverse events · girls with Turner syndrome who were treated with prepubertal growth hormone

The review found no eligible studies for this question.

1 finding from 1 review

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs placebo

Rate of symptom relief · women previously treated for endometrial cancer

The review found no eligible studies for this question.

1 finding from 1 review

Hormone replacement therapy for women previously treated for endometrial cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs placebo

Rate of tumour recurrence · women previously treated for endometrial cancer

It is very uncertain whether oestrogen replacement therapy changes rate of tumour recurrence compared with placebo (very low certainty).

1 finding from 1 review

Hormone replacement therapy for women previously treated for endometrial cancer 2018 · Cochrane Headline outcomes only
RR 1.17 [0.54, 2.5]
1 study · 1236 participants
Very low